Downregulation of transforming growth factor-beta1 in interferon-beta1a-treated MS patients.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 11571354.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors report an intense downregulation of transforming growth factor-beta1 (TGF-beta1) serum levels 4 weeks from start of interferon-beta1a (IFN-beta1a) treatment at 44 microg/week in 271 patients with relapsing-remitting MS, which was still present after 1 year (p < 0.001). In line with previous data, interleukin-10 serum levels did not vary significantly. These results indicate that the immunomodulatory effects of IFN-beta might not be restricted to the postulated anti-inflammatory mechanisms and address the role of TGF-beta in the pathogenesis of MS.
Medical subject headings
- Interferon-beta
- Multiple Sclerosis, Relapsing-Remitting
- Transforming Growth Factor beta